Glionova Therapeutics secures $5.7 million to take glioblastoma therapy into clinic

14-Nov-2014 - Sweden

Glionova Therapeutics announced that it has closed a SEK 42 million (US$ 5.7 million) Series A financing co-led by Novo Seeds and the company’s founding investor, HealthCap to take its lead compound GLN-1001 for treatment of glioblastoma into clinical trials.

“We welcome this significant support from our new as well as existing investors, who represent some of the most experienced in the global life sciences industry,” said Eugen Steiner, M.D., Ph.D., Chief Executive Officer of Glionova Therapeutics. “Their combined experience and financial backing will enable us to advance GLN-1001 into clinical development with the aim of making it available for patients with glioblastoma.“

Glionova Therapeutics is developing GLN-1001, a novel agent for potential disease modifying treatment for glioblastoma, the most common and most aggressive form of brain cancer. The project is based on recently published research from the Department of Medical Biochemistry and Biophysics at  the Karolinska Institutet and the Swedish national research infrastructure organisation Chemical Biology Consortium Sweden (CBCS), and the market opportunity identified by  KI Innovations.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances